Shares of Codexis Inc. (NASDAQ:CDXS) gapped up before the market opened on Monday . The stock had previously closed at $4.33, but opened at $4.35. Codexis shares last traded at $4.40, with a volume of 31,915 shares traded.

CDXS has been the subject of several research analyst reports. HC Wainwright initiated coverage on Codexis in a research report on Wednesday, June 1st. They set a “buy” rating and a $6.00 target price for the company. Zacks Investment Research lowered Codexis from a “hold” rating to a “sell” rating in a research note on Monday, July 18th.

The stock’s market capitalization is $176.61 million. The company’s 50-day moving average price is $4.13 and its 200 day moving average price is $3.79.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The business earned $8 million during the quarter, compared to analyst estimates of $7.49 million. Codexis’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.07) EPS. On average, equities research analysts anticipate that Codexis Inc. will post ($0.23) EPS for the current year.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.